Our Technology

IVX037

IVX037 is a bioselected, non-genetically modified, non-enveloped oncolytic virus with a positive-sense, single-stranded RNA genome. It uses CD55 and FcRn receptors for cell entry and is being evaluated in Phase 1b in combination with a PD-1 inhibitor. Preliminary findings support further investigation in KRAS/BRAF-mutant microsatellite-stable colorectal cancer, with activity also observed in ovarian cancer.

IVX055

IVX055 is a bioselected, non-genetically modified, non-enveloped oncolytic virus with a positive-sense, single-stranded RNA genome. It uses a different tumour-entry receptor from IVX037 and is being developed for additional solid tumours, including melanoma. Clinical entry is planned for Q1 2027, subject to completion of the preclinical and CMC package and the required approvals.

Differentiated Oncolytic RNA Immunotherapy Pipeline

Scientific Presentations

Date

Conference

Title

April 17 – 22 2026

American Association for Cancer Research (AACR) Annual Meeting 2026

Phase Ib clinical evaluation of a novel CD55- and FcRn-bioselected RNA oncolytic virus, IVX037, combined with sintilimab (anti-PD-1) in advanced microsatellite-stable colorectal cancer

High-Affinity Receptor Bio-Selected Novel Oncolytic RNA Virus, IVX055, Demonstrates Potent Anti-Tumour Activity in Human NSCLC, Hepatocellular Carcinoma, and Bladder Cancer with Potential for Immunotherapeutic Combinations

17 – 21 October 2025

European Society for Medical Oncology (ESMO) Congress in Berlin

Phase I Study of Intratumoural IVX037, a Novel CD55-Targeted Oncolytic RNA Virus, in Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC): Serum Biomarkers, Viral Kinetics, and KRAS Mutation Analysis

28 April 2025

American Association for Cancer Research (AACR) Annual Meeting 2025

Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS) colorectal,gastroesophageal or ovarian cancer

27 April 2025

American Association for Cancer Research (AACR) Annual Meeting 2025

Novel oncolytic RNA viruses, IVX037 and IVX055, demonstrate potent antitumor activity

21 November 2024

Australasian Gastro-Intestinal Trials Group (AGITG) 26th Annual Scientific Meeting

Phase 1a/b open-label, non-randomized, multi-centre clinical trial of intratumoral IVX037 monotherapy and in combination with anti-PD-1 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer: trial in progress

14 August 2024

Medical Oncology Group of Australia (MOGA) 45th Annual Scientific Meeting

Phase 1a/b open-label, non-randomized, multi-centre clinical trial of intratumoral IVX037 alone and in combination with anti-PD1 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer: trial in progress

6 November 2023

38^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phase 1a open-label, non-randomized, multi-centre clinical trial of intratumoral IVX037 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer: trial in progress

Pre-clinical / discovery

The company has a well-resourced team at its Newcastle R&D facility working on multiple projects, including:

Assessment of IVX037 and IVX055 in additional cancer types and in combination with other therapies such as RAS / RAF inhibitors.
Completion of the IVX055 preclinical and CMC package to support planned clinical entry in Q1 2027.
Investigation of alternative delivery approaches.
Assessment of opportunities in additional cancer indications.

In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories